Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | AHCY | P23526 | 1/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4160614 | 0.92 | ADORA2A (0.71) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL4159427 | 0.89 | ADORA3 (0.67) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL4159829 | 0.89 | ADORA2A (0.67) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL4160361 | 0.88 | ADORA2A (0.67) | ADORA2AADORA2BTMEM97ADORA3ADORA1 | |
| SCHEMBL4156007 | 0.85 | ADORA2A (0.72) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL3879857 | 0.85 | ADORA2A (0.75) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL4151756 | 0.83 | ADORA2A (0.70) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL4151768 | 0.83 | ADORA2A (0.70) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL4151745 | 0.83 | ADORA2A (0.70) | ADORA2AADORA2BAHCYADORA3ADORA1 | |
| SCHEMBL4152301 | 0.83 | ADORA2A (0.55) | ADORA2AADORA2BHIF1AAHCYTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | ADORA2A 33/4885ADORA2B 46/4885HIF1A 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.